107228-54-6

Usage

Uses

Given the provided materials do not specify the uses of 3,6-dichloro-4-ethylpyridazine, it is not possible to list its applications based on the information available. However, based on the general properties of pyridazine compounds, it can be inferred that 3,6-dichloro-4-ethylpyridazine may have potential applications in various chemical and pharmaceutical processes, such as:
Used in Chemical Synthesis:
3,6-dichloro-4-ethylpyridazine could be used as an intermediate in the synthesis of other organic compounds, leveraging its reactive sites for further functionalization.
Used in Pharmaceutical Industry:
It might serve as a building block in the development of pharmaceuticals, potentially contributing to the creation of new drugs due to its unique molecular structure.
Used in Agrochemicals:
3,6-dichloro-4-ethylpyridazine could also be utilized in the agrochemical sector for the development of pesticides or other crop protection agents, given its potential reactivity and structural features.

InChI:InChI=1/C6H6Cl2N2/c1-2-4-3-5(7)9-10-6(4)8/h3H,2H2,1H3

Upstream product

• 141-30-0 3,6-dichlorpyridazine 
• 802294-64-0 propionic acid 

Downstream Products

• 959841-42-0 5-[(6-chloro-4-ethylpyridazin-3-yl)(cyano)methyl]-2-fluorobenzonitrile 
• 959841-41-9 5-[(6-chloro-5-ethylpyridazin-3-yl)(cyano)methyl]-2-fluorobenzonitrile 

Relevant academic research and scientific papers

RAD51 INHIBITORS

This application is directed to inhibitors of RAD51 represented by the following structural formula, (I), and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.

THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i

TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where X, A?, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated recepto

Fused heterocyclic compounds useful as kinase modulators

Compounds having the formula (1), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, are usefuil as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR3, and R1, R2, R3, X and Y are as defined herein.

Preparation of substituted pyridazines

A novel process is described for preparing substituted pyridazines, where a less substituted pyridazine is reacted with a carboxylic acid in the presence of a silver ion as catalyst, using peroxydisulfate ion. The reaction is run at a temperature from about 40° to 80° C. in an aqueous solvent system and mineral acid. The substituted pyridazines are useful as intermediates to herbicidal and fungicidal compounds.